ELDECALCITOL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H50O5
Molecular Weight	490.715
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C)[C@H](C)CCCC(C)(C)O

InChI

InChIKey=FZEXGDDBXLBRTD-AYIMTCTASA-N

InChI=1S/C30H50O5/c1-20(9-6-15-29(3,4)34)24-13-14-25-22(10-7-16-30(24,25)5)11-12-23-19-26(32)28(27(33)21(23)2)35-18-8-17-31/h11-12,20,24-28,31-34H,2,6-10,13-19H2,1,3-5H3/b22-11+,23-12-/t20-,24-,25+,26-,27-,28-,30-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24101867 | https://www.chugai-pharm.co.jp/english/news/detail/20110121150000.html

Eldecalcitol (1α, 25-dihydroxy-2β-[3-hydroxypropyloxy] vitamin D3; ED-71) is an analog of the active form of vitamin D. Eldecalcitol has a hydroxypropyloxy group at the 2β-position of 1,25(OH)2D3. Compared with 1,25(OH)2D3, eldecalcitol has a higher affinity for serum vitamin D-binding protein (DBP), binds more weakly to vitamin D receptor, and shows lower potency in suppression of serum parathyroid hormone. The plasma half-life of eldecalcitol is longer than that of 1,25(OH)2D3, probably due to the higher affinity for DBP. In addition to regulation of calcium metabolism carried out by conventional vitamin D analogs, eldecalcitol possesses a strong inhibitory effect on bone resorption and causes a significant increase in bone mineral density. EDIROL (Eldecalcitol) has been approved for the treatment of osteoporosis in Japan.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vitamin D receptor 25 Target ID: CHEMBL1977 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24101867	Agonist 2678
Vitamin D-binding protein 2 Target ID: CHEMBL2259 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24101867	Binding Agent 1064

Conditions

Condition	Modality	Targets	Highest Phase	Product
Osteoporosis 97 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21902297 https://www.ncbi.nlm.nih.gov/pubmed/24101867	Primary		Approved 8429	EDIROL Approved Use EDIROL (Eldecalcitol) is indicated for the treatment of osteoporosis. Launch Date 2011

PubMed

Title	Date	PubMed
Spotlight on eldecalcitol in osteoporosis.	2012 Jan 1	22191725
Eldecalcitol for the treatment of osteoporosis.	2013	24101867
Eldecalcitol, a vitamin D analog, reduces bone turnover and increases trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.	2013 Nov	23774444

Patents

Sample Use Guides

In Vivo Use Guide

In general, for adults, take 0.75mcg of EDIROL (Eldecalcitol) once a day. It should be decreased according to your symptoms. 1 capsule contains 0.5mcg of the active ingredient.

Route of Administration: Oral

In Vitro Use Guide

Gene expression was analyzed in chondrocytes that were isolated from wildtype neonatal mice, cultured, and treated with ED-71 (Eldecalcitol) (10 nM). In primary chondrocytes cultured with ED-71, the gene expression of Erg and lubricin/proteoglycan 4 significantly increased, as compared to that of cells cultured without ED-71.

Name

Type

Language

ELDECALCITOL

Official Name

English

Eldecalcitol [WHO-DD]

Common Name

English

(5Z,7E)-2.BETA.-(3-HYDROXYPROPOXY)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1.ALPHA.,3.BETA.,25-TRIOL

Common Name

English

eldecalcitol [INN]

Common Name

English

ED-71

Code

English

ELDECALCITOL [MI]

Common Name

English

ELDECALCITOL [JAN]

Common Name

English

ELDECALCITOL [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C39713